<DOC>
	<DOCNO>NCT00483405</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving chemotherapy together monoclonal antibody may kill tumor cell . PURPOSE : This phase II trial study well give oxaliplatin capecitabine together cetuximab work treat patient advanced liver cancer .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine , Cetuximab Treating Patients With Advanced Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient advance hepatocellular carcinoma hepatic dysfunction treat oxaliplatin , capecitabine , cetuximab . Secondary - Determine safety regimen patient . - Determine overall survival patient treat regimen . - Determine time tumor progression patient treat regimen . OUTLINE : This open label , nonrandomized study . Patients receive oral capecitabine twice daily day 1-14 , cetuximab IV 60-120 minute day 1 , 8 , 15 , oxaliplatin IV 120 minute day 1 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3-4 week every 3 month thereafter .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Histologically confirm hepatocellular carcinoma Alphafetoprotein ( AFP ) &gt; 400 ng/mL compatible mass CT scan MRI Metastatic disease OR candidate surgical resection immediate liver transplantation At least 1 site measurable disease OR evaluable disease ( AFP 2 time upper limit normal [ ULN ] ) No evidence CNS metastasis ( unless CNS metastases stable &gt; 3 month ) PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Hemoglobin ≥ 9 g/dL Platelet count ≥ 100,000/mm³ Bilirubin ≤ 3 time ULN INR ≤ 1.5 AST ALT ≤ 5 time ULN Creatinine clearance &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity capecitabine , cetuximab , oxaliplatin murine product No comorbid condition deem investigator life expectancy &lt; 6 month No New York Heart Association class IIIIV coronary artery disease and/or heart failure No variceal bleed within past 60 day No cancer within past 5 year except cervical intraepithelial neoplasia , nonmelanoma skin cancer , ductal carcinoma situ , chronic lymphocytic leukemia , treat localized prostate cancer normal prostate specific antigen level No active drug alcohol abuse No prior allergic reaction therapeutic antibody No serious , uncontrolled infection No history uncontrolled seizure , CNS disorder , psychiatric disability , opinion investigator , would preclude study participation compliance No serious uncontrolled medical condition , opinion investigator , would preclude study participation No lack physical integrity upper gastrointestinal tract No malabsorption syndrome No known exist uncontrolled coagulopathy PRIOR CONCURRENT THERAPY : At least 4 week since prior participation investigational drug trial At least 4 week since prior major surgery recover At least 4 week since prior embolization , resection , ablation No prior EGFRtargeting therapy No prior systemic chemotherapy hepatic artery infusion chemotherapy No concurrent phenytoin No concurrent therapeutic warfarin Lowdose nontherapeutic warfarin maintain patency venous access device allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>